Add-on Acquisition • Life Science

Molecular Designs Acquires Lamda Biotech

On September 25, 2024, Molecular Designs acquired life science company Lamda Biotech

Acquisition Context

This is Molecular Designs’ 1st transaction in the Life Science sector.
This is Molecular Designs’ 1st transaction in the United States.
This is Molecular Designs’ 1st transaction in Missouri.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	September 25, 2024
Target	Lamda Biotech
Sector	Life Science
Buyer(s)	Molecular Designs
Deal Type	Add-on Acquisition

Target Company

Lamda Biotech

St. Louis, Missouri, United States

Lamda Biotech is a provider of research products for application in molecular biology, functional genomics, proteomics, and gene therapy. The Company offers PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain, and other protein and cell biology products. Lamda Biotech is headquartered in St. Louis, Missouri.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Molecular Designs

Birmingham, Alabama, United States

Category	Company
Founded	2019
Sector	Life Science

DESCRIPTION

Molecular Designs is a developer, manufacturer, and supplier of multiplex assays for molecular testing and research. Utilizing time-tested PCR to identify pathogens rapidly not only improves patient care but also advances antibiotic stewardship. Molecular Designs was founded in 2019 and is based in Birmingham, Alabama.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: Missouri	1 of 1
Country: United States	1 of 1
Year: 2024	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Missouri M&A - United States M&A - 2024 M&A